Potassium phosphate monobasicCAS# 7778-77-0 |
- Posaconazole hydrate
Catalog No.:BCC4234
CAS No.:1198769-38-8
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 7778-77-0 | SDF | Download SDF |
| PubChem ID | 516951 | Appearance | Powder |
| Formula | KH2PO4 | M.Wt | 136.09 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 300 mM in water | ||
| Chemical Name | potassium;dihydrogen phosphate | ||
| SMILES | OP(=O)(O)[O-].[K+] | ||
| Standard InChIKey | GNSKLFRGEWLPPA-UHFFFAOYSA-M | ||
| Standard InChI | InChI=1S/K.H3O4P/c;1-5(2,3)4/h;(H3,1,2,3,4)/q+1;/p-1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Commonly used in biological assay buffers. |
Potassium phosphate monobasic Dilution Calculator
Potassium phosphate monobasic Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 7.3481 mL | 36.7404 mL | 73.4808 mL | 146.9616 mL | 183.702 mL |
| 5 mM | 1.4696 mL | 7.3481 mL | 14.6962 mL | 29.3923 mL | 36.7404 mL |
| 10 mM | 0.7348 mL | 3.674 mL | 7.3481 mL | 14.6962 mL | 18.3702 mL |
| 50 mM | 0.147 mL | 0.7348 mL | 1.4696 mL | 2.9392 mL | 3.674 mL |
| 100 mM | 0.0735 mL | 0.3674 mL | 0.7348 mL | 1.4696 mL | 1.837 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 1,2-Dihydrotanshinquinone
Catalog No.:BCN2477
CAS No.:77769-21-2
- 1,7-Dihydroxy-3-methoxy-2-prenylxanthone
Catalog No.:BCN1354
CAS No.:77741-58-3
- (-)-Toddanol
Catalog No.:BCN3429
CAS No.:77715-99-2
- Arctigenin
Catalog No.:BCN6291
CAS No.:7770-78-7
- 6'''-Feruloylspinosin
Catalog No.:BCN2802
CAS No.:77690-92-7
- Enoximone
Catalog No.:BCC7155
CAS No.:77671-31-9
- ent-11,16-Epoxy-15-hydroxykauran-19-oic acid
Catalog No.:BCN1355
CAS No.:77658-46-9
- ent-9-Hydroxy-15-oxo-19-kauranoic acid
Catalog No.:BCN1356
CAS No.:77658-45-8
- ent-9-Hydroxy-15-oxo-16-kauren-19-oic acid
Catalog No.:BCN1357
CAS No.:77658-39-0
- Pterokaurene L3
Catalog No.:BCN4583
CAS No.:77658-38-9
- Boc-D-Ala-OH
Catalog No.:BCC3049
CAS No.:7764-95-6
- Toddanone
Catalog No.:BCN3430
CAS No.:77636-08-9
- Dehydrocrebanine
Catalog No.:BCN4328
CAS No.:77784-22-6
- Carasinol B
Catalog No.:BCN8226
CAS No.:777857-86-0
- GNF 2
Catalog No.:BCC3891
CAS No.:778270-11-4
- GNF 5
Catalog No.:BCC3892
CAS No.:778277-15-9
- Nelumol A
Catalog No.:BCN4749
CAS No.:77836-86-3
- (1R)-(+)-Alpha-Pinene
Catalog No.:BCC8275
CAS No.:7785-70-8
- Oglemilast
Catalog No.:BCC1817
CAS No.:778576-62-8
- Isopulegol
Catalog No.:BCN4974
CAS No.:7786-67-6
- Beta-Lipotropin (1-10), porcine
Catalog No.:BCC1009
CAS No.:77875-68-4
- Doxazosin Mesylate
Catalog No.:BCC1257
CAS No.:77883-43-3
- Dinaciclib (SCH727965)
Catalog No.:BCC3765
CAS No.:779353-01-4
- Longikaurin E
Catalog No.:BCN4329
CAS No.:77949-42-9
Doubling calcium and phosphate concentrations in neonatal parenteral nutrition solutions using monobasic potassium phosphate.[Pubmed:16537340]
J Am Coll Nutr. 2006 Feb;25(1):70-7.
BACKGROUND: Premature infants require high intakes of Ca and P to mimic fetal accretion rates. With the current phosphate salt used, adequate amounts cannot be provided due to the precipitation of Ca and P in TPN solutions. OBJECTIVE: To compare monobasic potassium phosphate (monobasic regimen) and monobasic plus dibasic potassium phosphate (dibasic regimen) on calcium phosphate solubility in 5 amino acid products, and to determine whether solubility differences observed in these products can be explained by buffering capacity. METHODS: TPN solutions were prepared according to standard clinical practice. The following amino acid products were used at 3% concentrations: Primene, Vamin N, TrophAmine, Aminosyn-PF, and Travasol. Dextrose 10%, standard electrolytes, heparin, vitamins and trace elements were added. Calcium (as gluconate) and phosphate (as monobasic or dibasic regimen) were added in one-to-one molar ratios from 0-45 mmol/L. Solutions were inspected macroscopically and microscopically for precipitation under three conditions: immediately, 24 h after preparation at room temperature, and 3 h later in a 37 degrees C water bath. Buffering capacity was determined for each amino acid product by titrating with standardized 0.1 M NaOH. RESULTS: Variations in Ca:P solubility and buffer capacity exist between amino acid solutions. With Primene and Vamin no macroscopic or microscopic precipitation was detected up to 45 mmol/L using monobasic regimen, compared to 25 mmol/L using dibasic regimen with Trophamine. Buffer capacity did not account for the solubility differences observed between the five amino acid products, which were related to the pH of the final solution. CONCLUSIONS: These data will allow clinicians to double the current concentrations of calcium and phosphate in neonatal TPN solutions using monobasic regimen. Although this is particularly relevant to situations when fluid intake is restricted, the effect of the acid load needs to be investigated in extremely low birth weight infants.
